Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Baiya SARS-CoV-2 Vax 2
- Development stage
- Phase 2
- Lead developer
- Baiya Phytopharm
- Modality
- Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Baiya SARS-CoV-2 Vax 2 is a second-generation, plant-produced recombinant protein subunit vaccine targeting COVID-19. It is based on the receptor binding domain (RBD) of the prototype (Wuhan) SARS-CoV-2 spike protein, produced in Nicotiana benthamiana plants and formulated with the adjuvant 3M-052-AF-alum, which acts as a toll-like receptor (TLR) 7/8 agonist. Preclinical studies demonstrated that Baiya SARS-CoV-2 Vax 2 induces strong RBD-specific IgG and neutralizing antibody responses in animal models, providing protection against multiple variants of concern including Alpha, Beta, Gamma, Delta, and Omicron. The vaccine has shown favorable safety and tolerability profiles in non-human primates and rats. Baiya SARS-CoV-2 Vax 2 is being developed primarily for COVID-19 prevention[1][2][3].
- Brand names
- baiya sars-cov-2 vax 2
- Other names
- none
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on Baiya SARS-CoV-2 Vax 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baiya SARS-CoV-2 Vax 2.